|
Volumn 17, Issue 5, 2001, Pages 421-432
|
Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist
a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
LATANOPROST;
PROSTAGLANDIN DP RECEPTOR;
PROSTAGLANDIN E RECEPTOR;
PROSTAGLANDIN EP1 RECEPTOR;
PROSTAGLANDIN EP3 RECEPTOR;
PROSTAGLANDIN EP4 RECEPTOR;
PROSTAGLANDIN F2 ALPHA ISOPROPYL ESTER;
PROSTAGLANDIN FP RECEPTOR;
PROSTAGLANDIN IP RECEPTOR;
PROSTAGLANDIN RECEPTOR;
PROSTAGLANDIN RECEPTOR STIMULATING AGENT;
PROSTAGLANDIN TP RECEPTOR;
TRAVOPROST;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ARTICLE;
BINDING AFFINITY;
CAT;
CONTROLLED STUDY;
DOSE RESPONSE;
DOSE TIME EFFECT RELATION;
DRUG EFFICACY;
DRUG POTENCY;
DRUG RECEPTOR BINDING;
DRUG TOLERABILITY;
EYE IRRITATION;
HUMAN;
INCIDENCE;
INTRAOCULAR HYPERTENSION;
INTRAOCULAR PRESSURE;
MIOSIS;
MONKEY;
NONHUMAN;
PROSTAGLANDIN RELEASE;
RABBIT;
RECEPTOR BINDING;
|
EID: 0035203853
PISSN: 10807683
EISSN: None
Source Type: Journal
DOI: 10.1089/108076801753266802 Document Type: Article |
Times cited : (123)
|
References (23)
|